Page 264 - The Vasculitides Volumes 2

240 Antoine Sreih and Peter A. Merkel

[55] Harnden, A., Takahashi, M., Burgner, D. Kawasaki disease. BMJ 2009; 338:b1514;
Furukawa, T., Kishiro, M., Akimoto, K., et al. Effects of steroid pulse therapy on
immunoglobulin-resistant Kawasaki disease. Arch. Dis. Child 2008; 93:142-146.

[56] Durongpisitkul, K., Gururaj, V. J., Park, J. M., et al. The prevention of coronary artery
aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and
immunoglobulin treatment. Pediatrics 1995; 96:1057-1061.

[57] Newburger, J. W., Sleeper, L. A., McCrindle, B. W., et al. Randomized trial of pulsed
corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med.
2007; 356:663-675.

[58] Hoffman, G. S. Large-vessel vasculitis: unresolved issues. Arthritis Rheum. 2003; 48:
2406-2414.

[59] Maksimowizc-McKinnon, K., Clark, T. M., Hoffman, G. S. Takayasu arteritis and giant
cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 2009; 88:221-
226.

[60] Grayson, P. C., Tomasson, G., Cuthbertson, D., et al. Association of vascular physical
examination findings and arteriographic lesions in large vessel vasculitis. J. Rheumatol.
2012; 39:303-309.

[61] Weyand, C. M., Goronzy, J. J. Giant-cell arteritis and polymyalgia rheumatica. N. Engl.
J. Med. 2014; 371:50-57.

[62] Maziumzadeh, M., Hunder, G. G., Easley, K. A., et al. Treatment of giant cell arteritis
using induction therapy with high-dose glucocorticoids: a double-blind, placebo-
controlled, randomized prospective clinical trial. Arthritis Rheum. 2006; 54:3310-3318.

[63] Spiera, R. F., Mitnick, H. J., Kupersmith, M., et al. A prospective, double-blind,
randomized, placebo controlled trial of methotrexate in the treatment of giant cell
arteritis (GCA). Clin. Exp. Rheumatol. 2001; 19:495-501.

[64] Jover, J. A., Hernández-García, C., Morado, I. C., et al. Combined treatment of giant-
cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-
controlled trial. Ann. Intern. Med. 2001; 134:106-114.

[65] Hoffman, G. S., Cid, M. C., Hellmann, D. B., et al. A multicenter, randomized, double-
blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
Arthritis Rheum. 2002; 46:1309-1318.

[66] Mahr, A. D., Jover, J. A., Spiera, R. F., et al. Adjuvant methotrexate for treatment of
giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007; 56:
2789-2797.

[67] Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., et al. Infliximab for maintenance of
glucocorticoid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern.
Med. 2007; 146:621-630.

[68] Martinez-Taboada, V. M., Rodriguez-Valverde, V., Carreno, L., et al. A double-blind
placebo controlled trial of etanercept in patients with giant cell arteritis and
corticosteroid side effects. Ann. Rheum. Dis. 2008; 67:625-630.

[69] Seror, R., Baron, G., Hachulla, E., et al. Adalimumab for steroid sparing in patients
with giant-cell arteritis: results of a muticentre randomised controlled trial. Ann. Rheum.
Dis. 2013 July 29 [Epub. ahead of print].

[70] Salvarani, C., Hunder, G. G. Tumor necrosis factor blocking agents in polymyalgia
rheumatica and giant cell arteritis. Ann. Intern. Med. 2008; 148:167-168.

Complimentary Contributor Copy